In the landscape of KRAS-mutated cancer therapeutics, several strategies such as small molecule inhibitors (targets upstream & downstream effectors, direct KRAS and its regulators, cell cycle regulators); siRNA candidates; cancer vaccines; PROteolysis TArgeting Chimers (PROTACs); Antibody–Drug conjugates (ADCs); and Immunotherapies are being developed and studied in preclinical and clinical models [9–12]. The gene discussed is KRAS; the disease is cancer.